Drug Sentece Context
Table 1. Analysis of context sentence of dupilumab gene in 11 abstracts.
|Dupilumab is a fully human monoclonal antibody against the alfa subunit of interleukin (IL)-4 receptor that blocks signalling from both IL-4 and IL-13, which are key type 2 cytokines in the pathophysiology of atopic dermatitis (AD). […] In a paper of Deleuran et al. the authors showed long term safety and efficacy of dupilumab; they reported viral upper respiratory tract infection, cough and influenza in about 2% of patients.
|Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 (IL-4) and IL-13. […] Dupilumab is approved for inadequately controlled moderate-to-severe AD.1.
|In particular, there are no current clinical data about the interference exerted by dupilumab, a biologic drugs blocking IL-4 and IL-13, used for adult atopic dermatitis. […] Furthermore, dupilumab has been proved to be efficacious also in exacerbations of asthma, and it is known that viral infections can worsen asthma. […] Therefore, the current data seem to suggest that treatment with dupilumab should not be stopped during COVID-19 pandemic.
|We have read with great interest the letter of the European Task Force on Atopic Dermatitis (ETFAD) on SARS-CoV-2-infection and atopic dermatitis published in JEADV (March 2020)1 in which the authors state: “Targeted treatment selectively interfering with type-2 inflammation such as dupilumab is not considered to increase the risk for viral infections and might thus be preferred …in a situation such as COVID-19 pandemic”.1.
|A patient with severe CRSwNP, asthma, and NSAIDS received dupilumab treatment.
|Apremilast, acitretin and dupilumab, have favorable safety data, and may be safely initiated and continued in uninfected patients.
|With many drugs being tried in the management and treatment of COVID-19, dupilumab is one such monoclonal antibody that has come under the limelight for its possible role as an adjunct therapy in COVID-19 position. […] There are isolated case reports and series that document a milder course of COVID-19 infection in patients who have already been on dupilumab therapy for treatment of conditions such as atopic dermatitis and chronic rhino-sinusitis with nasal polyp. […] In this article, a non-systematic critical analysis of dupilumab was performed to delve into this hypothesis further.
|Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. […] Transitioning to dupilumab should be executed strategically-tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. […] Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.
|The aim of this study was to assess incidence and disease course of COVID-19 in patients with severe asthma on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab), as compared with COVID-19 data from the general Dutch population.
|Some reports indicated that treatment with benralizumab, dupilumab, and omalizumab in patients with severe asthma was not associated with significant adverse effects during COVID-19.